PL376754A1 - Związki heterocykliczne użyteczne jako aktywatory Nurr-1 - Google Patents

Związki heterocykliczne użyteczne jako aktywatory Nurr-1

Info

Publication number
PL376754A1
PL376754A1 PL376754A PL37675404A PL376754A1 PL 376754 A1 PL376754 A1 PL 376754A1 PL 376754 A PL376754 A PL 376754A PL 37675404 A PL37675404 A PL 37675404A PL 376754 A1 PL376754 A1 PL 376754A1
Authority
PL
Poland
Prior art keywords
nurr
activators
heterocyclic compounds
compounds useful
heterocyclic
Prior art date
Application number
PL376754A
Other languages
English (en)
Inventor
Samuel Hintermann
Bastian Hengerer
Boris Schmidt
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL376754A1 publication Critical patent/PL376754A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL376754A 2003-02-14 2004-02-13 Związki heterocykliczne użyteczne jako aktywatory Nurr-1 PL376754A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0303503.7A GB0303503D0 (en) 2003-02-14 2003-02-14 Organic compounds

Publications (1)

Publication Number Publication Date
PL376754A1 true PL376754A1 (pl) 2006-01-09

Family

ID=9953078

Family Applications (1)

Application Number Title Priority Date Filing Date
PL376754A PL376754A1 (pl) 2003-02-14 2004-02-13 Związki heterocykliczne użyteczne jako aktywatory Nurr-1

Country Status (14)

Country Link
US (1) US7432293B2 (pl)
EP (1) EP1597243A1 (pl)
JP (1) JP2006517564A (pl)
CN (2) CN100475795C (pl)
AR (1) AR043168A1 (pl)
AU (1) AU2004212151B2 (pl)
BR (1) BRPI0407479A (pl)
CA (1) CA2515847A1 (pl)
GB (1) GB0303503D0 (pl)
MX (1) MXPA05008584A (pl)
PE (1) PE20050193A1 (pl)
PL (1) PL376754A1 (pl)
TW (1) TW200502225A (pl)
WO (1) WO2004072050A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2887054T3 (es) 2003-04-11 2021-12-21 Ptc Therapeutics Inc Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
EP1815206B1 (en) * 2004-10-13 2016-04-06 PTC Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
CA2603402C (en) * 2005-04-08 2017-10-31 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
WO2006114400A1 (en) 2005-04-26 2006-11-02 Neurosearch A/S Novel oxadiazole derivatives and their medical use
IN2014CN04406A (pl) 2006-03-30 2015-09-04 Ptc Therapeutics Inc
FR2903107B1 (fr) 2006-07-03 2008-08-22 Sanofi Aventis Sa Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
FR2903105A1 (fr) 2006-07-03 2008-01-04 Sanofi Aventis Sa Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique
FR2903108B1 (fr) * 2006-07-03 2008-08-29 Sanofi Aventis Sa Utilisation de derives d'imidazo[1,2-a] pyridine-2-carboxamides en therapeutique.
PT2059513E (pt) 2006-09-08 2013-04-30 Ptc Therapeutics Inc Processo para a preparação de ácidos 1,2,4-oxadiazolebenzóicos
FR2906250B1 (fr) * 2006-09-22 2008-10-31 Sanofi Aventis Sa Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
WO2008130370A1 (en) 2006-09-25 2008-10-30 Ptc Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression
SG10201609581TA (en) * 2006-09-25 2016-12-29 Ptc Therapeutics Inc Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
CL2007002923A1 (es) * 2006-10-12 2008-06-06 Ptc Therapeutics Inc Soc Organ Metodo para el tratamiento, prevencion o manejo de una enfermedad asociada con una mutacion sin sentido tal como cancer, diabetes o enfermedad pulmonar, que consiste en administrar a un paciente una cantidad efectiva de acido 3-[5-(2-fluoro-fenil)-[1
ES2663517T3 (es) 2007-08-27 2018-04-13 Dart Neuroscience (Cayman) Ltd Compuestos terapéuticos de isoxazol
WO2010000372A2 (en) 2008-06-09 2010-01-07 Ludwig-Maximilians-Universität München New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
WO2010008831A2 (en) * 2008-06-24 2010-01-21 Irm Llc Compounds and methods for modulating g protein-coupled receptors
FR2933609B1 (fr) 2008-07-10 2010-08-27 Fournier Lab Sa Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson.
WO2011009484A1 (en) * 2009-07-22 2011-01-27 Novartis Ag Arylpyrazoles and arylisoxazoles and their use as pkd modulators
FR2950053B1 (fr) 2009-09-11 2014-08-01 Fournier Lab Sa Utilisation de derives d'indole benzoique comme activateurs de nurr-1, pour le traitement de la maladie de parkinson
FR2955110A1 (fr) * 2010-01-08 2011-07-15 Fournier Lab Sa Nouveaux derives de type pyrrolopyridine benzoique
NZ610145A (en) * 2010-10-14 2015-02-27 Daiichi Sankyo Co Ltd Acylbenzene derivative having a hypoglycemic action and/or a β cell- or pancreas-protecting action
ES2759902T3 (es) * 2013-11-05 2020-05-12 Bayer Animal Health Gmbh Nuevos compuestos para combatir artrópodos
TWI695717B (zh) 2014-03-06 2020-06-11 美商 Ptc 治療公司 1,2,4-二唑苯甲酸之鹽及醫藥組合物
HK1251965A1 (zh) 2015-10-30 2019-05-10 Ptc医疗公司 用於治疗癫痫的方法
JP7283699B2 (ja) 2017-05-12 2023-05-30 マックス-プランク-ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 黒色腫の治療または予防において使用するためのフェニル-ヘテロ環-フェニル誘導体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04295470A (ja) * 1991-03-22 1992-10-20 Wakamoto Pharmaceut Co Ltd モノアミンオキシダーゼ−b酵素阻害活性を有する1,2,4−オキサジアゾール誘導体及びその製造法
WO1997003967A1 (en) * 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
DE19620041A1 (de) * 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
DE19816880A1 (de) * 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
JP2000080086A (ja) * 1998-07-01 2000-03-21 Takeda Chem Ind Ltd レチノイド関連受容体機能調節剤
CA2332178A1 (en) * 1998-07-01 2000-01-13 Takeda Chemical Industries, Ltd. Retinoid-associated receptor function regulating agent
EP1070708B1 (en) * 1999-07-21 2004-01-14 F. Hoffmann-La Roche Ag Triazole derivatives
CN1313465C (zh) * 1999-08-19 2007-05-02 Nps药物有限公司 杂多环化合物及其用于制备代谢性谷氨酸受体拮抗剂的应用
CA2438991C (en) * 2001-02-21 2010-08-17 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EP1405636A4 (en) * 2001-06-26 2009-04-15 Takeda Pharmaceutical FUNCTIONAL REGULATOR FOR RETINOID RELATIVE RECEPTOR

Also Published As

Publication number Publication date
AU2004212151A1 (en) 2004-08-26
AR043168A1 (es) 2005-07-20
MXPA05008584A (es) 2005-11-04
PE20050193A1 (es) 2005-04-11
GB0303503D0 (en) 2003-03-19
EP1597243A1 (en) 2005-11-23
US7432293B2 (en) 2008-10-07
CN100475795C (zh) 2009-04-08
BRPI0407479A (pt) 2006-02-07
CN1747942A (zh) 2006-03-15
AU2004212151B2 (en) 2008-09-04
CA2515847A1 (en) 2004-08-26
JP2006517564A (ja) 2006-07-27
TW200502225A (en) 2005-01-16
US20060089365A1 (en) 2006-04-27
CN101665469A (zh) 2010-03-10
WO2004072050A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
IL174375A0 (en) Novel heterocyclic compounds as hsp90-inhibitors
IL209082A0 (en) Fushed heterocyclic compounds
PL377087A1 (pl) Związki heterocykliczne
EP1551801A4 (en) NOVEL GAMMA-LACTAMES AS INHIBITORS OF BETA-SECRETASE
PT1636192E (pt) Compostos de heteroarilo com substituição 3-alquilidenohidrazino como activadores do receptor de trombopoietina
GB0304424D0 (en) Novel compounds
SG131944A1 (en) N3-substituted imidazopyridine-derivatives as c-kit inhibitors
EP1476425A4 (en) Heterocyclic Aryl Sulphonamidocyclic Compounds
EP1648885A4 (en) NEW CONNECTIONS
GB0305426D0 (en) Novel compounds
GB0403135D0 (en) Chiral compounds
GB0304809D0 (en) Novel compounds
GB0302431D0 (en) Novel compounds
GB0302546D0 (en) Novel compounds
HK1085730A (en) Heterocyclic compounds useful as nurr-1 activators
ZA200509643B (en) 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators
HK1089770A (en) Novel heterocyclic compounds as hsp90-inhibitors
AU2003906640A0 (en) Heterocyclic compounds
GB0301592D0 (en) Novel compounds
GB0300483D0 (en) Novel compounds
GB0300481D0 (en) Novel compounds
GB0304802D0 (en) Novel compounds
GB0305285D0 (en) Novel compounds
GB0305165D0 (en) Novel compounds
GB0305292D0 (en) Novel compounds

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)